Medipost
Seongnam
About Medipost
MEDIPOST’s mission is to help patients with incurable diseases and unravel unmet medical needs through stem cells and regenerative medicine.MEDIPOST has been making resilient efforts despite difficulties and challenges in the field of stem cell research and commercialization, while upholding strong corporate ethics and values. Today, MEDIPOST is the global stem cell therapeutics field with the world’s first regulatory-approved allogeneic human Umbilical Cord Blood-derived Mesenchymal Stem Cell(hUCB-MSC) product named CARTISTEM® for patients with knee Osteoarthritis(OA), launched in Korean market in 2012.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $394.6M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jan 2026)
- Ticker: kosdaq:078160
- Website: medi-post.com
- Phone: +82 2-3465-6677
Industries & Categories
Biotechnology
Canonical: https://fsome.com/organization/medipost-52183 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.